Peri-operative and Post-operative Management of Hemophiliac Patients without Inhibitors

  • Maria Elisa Mancuso
  • Elena Santagostino


Orthopedic surgery in patients with hemophilia should be planned by the surgeon together with the hemophilia specialist and the physiotherapist, in order to establish a long-term program that integrates surgery with medical and rehabilitative interventions. Orthopedic surgery should be performed in centres that are able to provide hematologic expertise, medical support, and laboratory monitoring of coagulation throughout the period of hospitalization.


Human Immunodeficiency Virus Factor Viii Inhibitor Development Immune Serum Globulin Hereditary Bleeding Disorder 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    Mannucci PM, Ruggeri ZM, Pareti FI, Capitanio A (1977) 1-Deamino-8-D-Arginine vasopressin: a new pharmacological approach to the management of haemophilia and von Willebrand’s disease. Lancet i:869–872CrossRefGoogle Scholar
  2. 2.
    Santagostino E, Mannucci PM (2000) Guidelines on replacement therapy for haemophilia and inherited coagulation disorders in Italy. Haemophilia 6:1–10PubMedCrossRefGoogle Scholar
  3. 3.
    United Kingdom Haemophilia Centre Doctors’ Organisation (UKHCDO) (2003) Guidelines on the selection and use of therapeutic products to treat haemophilia and other hereditary bleeding disorders. Haemophilia 9:1–23CrossRefGoogle Scholar
  4. 4.
    Fletcher ML, Trowell JM, Craske J et al (1983) Non-A, non-B hepatitis after transfusion of factor VIII in unfrequently treated patients. Br Med J 287:1754–1757CrossRefGoogle Scholar
  5. 5.
    Kernoff PBA, Lee CA, Karayanis P, Thomas HC (1985) High risk of non-A, non-B hepatitis after a first exposure to volunteer or commercial clotting factor concentrates: effects of prophylactic immune serum globulin. Br J Haematol 60:469–479PubMedCrossRefGoogle Scholar
  6. 6.
    Powell DL, Whitener CJ, Dye CE et al (2005) Knee and hip arthroplasty infection rates in persons with haemophilia: a 27 year single center experience during the HIV epidemic. Haemophilia 11:233–239PubMedCrossRefGoogle Scholar
  7. 7.
    Wilde JT, Lee CA, Collins P et al (1999) Increased bleeding associated with protease inhibitor therapy in HIV-positive patients with bleeding disorders. Br J Haematol 107: 556–569PubMedCrossRefGoogle Scholar
  8. 8.
    Martinowitz U, Schulman S, Gitel S et al (1992) Adjusted dose continuous infusion of factor VIII in patients with haemophilia A. Br J Haematol 82:729–734PubMedCrossRefGoogle Scholar
  9. 9.
    Schulman S, Gitel S, Martinowitz U (1994) Stability of factor VIII concentrates after reconstitution. Am J Hematol 45:217–223PubMedCrossRefGoogle Scholar
  10. 10.
    Schulman S, Varon D, Keller N et al (1994) Monoclonal purified FVIII for continuous infusion: stability, microbiological safety and clinical experience. Thromb Haemost 72:403–407PubMedGoogle Scholar
  11. 11.
    Chowdary P, Dasani H, Jones JA et al (2001) Recombinant factor IX (BeneFix) by adjusted continuous infusion: a study of stability, sterility and clinical experience. Haemophilia 7:140–145PubMedCrossRefGoogle Scholar
  12. 12.
    Sharathkumar A, Lillicrap D, Blanchette VS et al (2003) Intensive exposure to factor VIII is a risk factor for inhibitor development in mild hemophilia A. J Thromb Haemost 1:1228–1236PubMedCrossRefGoogle Scholar
  13. 13.
    White B, Cotter M, Byrne M et al (2000) High responding factor VIII inhibitors in mild haemophilia — is there a link with recent changes in clinical practice? Haemophilia 6:113–115PubMedCrossRefGoogle Scholar
  14. 14.
    Rickard KA (1995) Guidelines for therapy and optimal dosages of coagulation factors for treatment of bleeding and surgery in haemophilia. Haemophilia 1(Suppl 1):8–13CrossRefGoogle Scholar
  15. 15.
    Dingli D, Gastineau DA, Gilchrist GS et al (2002) Continuous factor VIII infusion therapy in patients with haemophilia A undergoing surgical procedures with plasma-derived or recombinant factor VIII concentrates. Haemophilia 8:629–634PubMedCrossRefGoogle Scholar

Copyright information

© Springer 2008

Authors and Affiliations

  • Maria Elisa Mancuso
    • 1
  • Elena Santagostino
    • 2
  1. 1.Angelo Bianchi Bonomi Hemophilia and Thrombosis Center, Department of Internal Medicine and Medical SpecialtiesIRCCS Maggiore Hospital, Mangiagalli and Regina Elena FoundationMilanItaly
  2. 2.Hemophilia Outpatient Clinic, Angelo Bianchi Bonomi Hemophilia and Thrombosis Center, Department of Internal Medicine and Medical SpecialtiesIRCCS Maggiore Hospital, Mangiagalli and Regina Elena FoundationMilanItaly

Personalised recommendations